Dr. June Y. Hou received her undergraduate degree at Yale College with Honors, and completed medical school at Georgetown University School of Medicine. After completing her residency training at Yale New Haven Hospital, she pursued a gynecologic oncology fellowship at Albert Einstein College of Medicine, Montefiore Medical Center. She is board certified in Obstetrics and Gynecology, Gynecologic Oncology, and Palliative Medicine.
She joins the faculty at Columbia University Medical Center with a research interest in early phase clinical trials, and quality of life measures in patients undergoing clinical trials for gynecologic malignancies. A past recipient of a career development grant focusing on molecular pathogenesis of ovarian cancer and rare uterine cancers, Dr. Hou has given multiple nationally-recognized presentations based on her work, and has lead numerous clinical trials. Clinically, Dr. Hou is certified in minimally invasive surgery, including robotic-assisted surgery. Her expertise includes chemotherapeutics and complex pelvic surgeries. Her goal is to provide compassionate and individualized care to all women with pre-malignant or gynecological cancers.
|Obstetrics & Gynecology||[ CLOSED ] A study for women with ovarian cancer who have failed chemotherapy using study drug Liposome-Encapsulated Doxorubicin Hydrochloride|
|Gynecologic Cancer||[ CLOSED ] Study of the Effects of Drug in Conjunction with Hormone Therapy in Patients with Endometrial Carcinoma|
|Cancer||Study of Drug in Patients with Advanced Solid Malignancies and Lymphoma|
|Solid Tumors||[ CLOSED ] Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors|
|Gynecologic Cancer||Study of REGN4018 Alone or in Combination with Cemiplimab in Patients with Ovarian Cancer|
|Gynecologic Cancer||[ CLOSED ] Study of SPL-108 Injections Used in Combination with Paclitaxel in Patients with Advanced Ovarian Epithelial Cancer|
|Solid Tumors||[ CLOSED ] Study of SY-1365 in Adult Patients with Advanced Solid Tumors|
|Gynecologic Cancer||[ CLOSED ] Study of TSR-042 and Niraparib in Treatment of Stage III or IV Epithelial Ovarian Cancer|
|Obstetrics & Gynecology||[ CLOSED ] VGX-3100 Followed by Electroporation with Cellectra for HPV-related High-Grade Squamous Intraepithelial Lesion of Cervix (REVEAL 2)|
|Solid Tumors||[ CLOSED ] A Study of Rucaparib as Treatment for Solid Tumors|
|Cancer||A Study of MORAb-202 in Participants With Selected Tumor Types|